Table 1.

Association results for 23 novel risk variants for prostate cancer.

SNP ID	Chromosome, positionb	Nearby Genes	Allelesc	European 35,093 cases 34,599 controls			African 5,327 cases 5,136 controls			Japanese 2,563 cases 4,391 controls			Latino 1,034 cases 1,046 controls			Multiethnic 44,107 cases 45,172 controls		PHet valued
Risk Loci Revealed in European Ancestry Meta-Analysis				OR	P	RAFa	OR	P	RAFa	OR	P	RAFa	OR	P	RAFa	OR	P
rs17599629	1q21, 150658287	GOLPH3L	G/A	1.10	5.9×10-11	0.22	1.09	0.13	0.08	0.97	0.48	0.18	0.92	0.23	0.26	1.08	2.6×10-9	8.6×10-3
rs9287719	2p25, 10710730	NOL10	C/T	1.07	1.8×10-8	0.46	1.00	0.98	0.26	1.07	0.06	0.42	1.00	0.99	0.45	1.06	2.8×10-8	0.21
rs10009409	4q13, 73855253	COX18	T/C	1.09	2.1×10-10	0.32	1.02	0.56	0.35	1.10	0.02	0.56	1.00	0.96	0.50	1.08	2.3×10-10	0.12
rs4713266	6p24, 11219030	NEDD9	C/T	1.07	3.9×10-8	0.52	1.07	0.03	0.78	1.06	0.21	0.23	1.02	0.81	0.40	1.06	2.9×10-9	0.89
rs115457135	6p22, 30073776	TRIM31	A/G	1.08	1.9×10-8	0.22	1.01	0.91	0.15	1.01	0.87	0.27	1.03	0.69	0.26	1.07	1.4×10-7	0.25
rs115306967	6p21, 32400939	HLA-DRB6	G/C	1.08	2.7×10-9	0.65	0.92	0.02	0.81	1.09	0.29	0.81	1.01	0.86	0.76	1.06	8.7×10-7	5.2×10-4
rs56232506	7p12, 47437244	TNS3	A/G	1.07	1.8×10-9	0.45	0.99	0.76	0.13	1.00	0.99	0.31	1.11	0.12	0.52	1.06	8.9×10-9	0.13
rs17694493	9p21, 22041998	CDKN2B-AS1	G/C	1.10	4.0×10-8	0.14	1.00	0.97	0.11	1.04	0.78	0.02	0.78	0.04	0.08	1.08	1.1×10-6	0.01
rs76934034	10q11, 46082985	MARCH8	T/C	1.14	4.8×10-9	0.91	0.98	0.88	0.98			-e	1.06	0.64	0.92	1.13	1.1×10-8	0.39
rs11214775	11q23, 113807181	HTR3B	G/A	1.08	3.0×10-8	0.71	1.04	0.22	0.71	1.02	0.70	0.71	1.06	0.47	0.81	1.07	4.5×10-8	0.39
rs80130819	12q13, 48419618	RP1-228P16.4	A/C	1.13	4.3×10-8	0.91	1.28	0.02	0.98			-e	1.22	0.17	0.94	1.14	2.2×10-9	0.44
rs8014671	14q24, 71092256	TTC9	G/A	1.07	1.3×10-8	0.59	1.00	0.85	0.46	1.03	0.40	0.36	0.98	0.75	0.60	1.06	2.5×10-7	0.09
rs2807031	Xp11, 52896949	XAGE3	C/T	1.07	8.5×10-10	0.18	1.06	0.02	0.22	1.17	0.16	0.05	1.02	0.82	0.09	1.07	2.7×10-11	0.77
rs6625711	Xq13, 70139850	SLC7A	A/T	1.07	6.3×10-12	0.41	0.92	0.004	0.83	0.99	0.86	0.48	0.97	0.52	0.61	1.04	6.4×10-7	8.4×10-6
rs4844289	Xq13, 70407983	NLGN3/BCYRN1	G/A	1.05	1.3×10-9	0.39	0.99	0.58	0.68	1.00	0.99	0.72	1.09	0.05	0.59	1.04	8.9×10-8	0.04
Risk Loci Revealed in Multiethnic Meta-Analysis
rs1775148	1q32, 205757824	SLC41A1	C/T	1.06	1.0×10-5	0.27	1.06	0.04	0.63	1.12	2.0×10-3	0.52	1.02	0.82	0.66	1.06	3.8×10-8	0.40
rs9443189	6q14, 76495882	MYO6	A/G	1.07	5.2×10-5	0.86	1.11	4.5×10-4	0.47	1.07	0.08	0.68	1.01	0.93	0.86	1.08	3.9×10-8	0.64
rs7153648	14q23, 61122526	SIX1	C/G	1.09	6.8×10-4	0.06	1.11	8.8×10-4	0.34	1.17	1.4×10-4	0.30	1.12	0.27	0.10	1.11	2.0×10-9	0.50
rs12051443	16q22, 71691329	PHLPP2	A/G	1.06	1.1×10-5	0.34	1.09	0.01	0.25	1.10	0.02	0.65	1.06	0.34	0.50	1.06	3.0×10-8	0.69
rs12480328	20q13, 49527922	ADNP	T/C	1.13	1.6×10-7	0.93	1.14	2.3×10-3	0.87	1.30	7.7×10-4	0.94	0.97	0.81	0.93	1.13	4.6×10-11	0.18
rs1041449	21q22, 42901421	TMPRSS2	G/A	1.06	2.6×10-7	0.44	1.07	0.03	0.39	1.02	0.79	0.12	1.03	0.65	0.44	1.06	2.8×10-8	0.84
rs2238776	22q11, 19757892	TBX1	G/A	1.09	1.6×10-7	0.80	0.98	0.81	0.95	1.08	0.03	0.60	1.09	0.22	0.73	1.08	1.8×10-8	0.60
Risk Loci Revealed in Early-Onset Meta-Analysisf
rs636291	1p35, 10556097	PEX14	A/G	1.18	2.1×10-8	0.16

^aRisk Allele Frequency

^bGenome Build 37

^cRisk allele/Other allele

^dP-value for effect heterogeneity across populations.

^eMinor allele frequency <1%

^fAnalysis limited to European ancestry populations as only small numbers of early onset cases (≤55 years) were available in the other populations.